Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sedana Medical AB ( (SE:SEDANA) ) has issued an announcement.
Sedana Medical AB reported a 4% increase in net sales for Q3 2025 compared to the same period in 2024, with a notable improvement in EBITDA performance despite market challenges. The company experienced improved cash flow from operations and a reduction in operating costs, although cash flow from investments remained negative due to ongoing registration preparation work in the USA. The financial results reflect Sedana Medical’s strategic focus on enhancing operational efficiency and expanding its market presence in the medtech and pharmaceutical sectors.
The most recent analyst rating on (SE:SEDANA) stock is a Hold with a SEK12.00 price target. To see the full list of analyst forecasts on Sedana Medical AB stock, see the SE:SEDANA Stock Forecast page.
More about Sedana Medical AB
Sedana Medical AB (publ) is a pioneer medtech and pharmaceutical company focused on inhaled sedation to improve patients’ life during and beyond sedation. Through the combined strengths of the medical device Sedaconda ACD and the pharmaceutical Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated patients in intensive care. Sedana Medical was founded in 2005 and is listed on Nasdaq Stockholm. The company’s head office is in Stockholm, Sweden.
Average Trading Volume: 293,368
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK1.25B
For an in-depth examination of SEDANA stock, go to TipRanks’ Overview page.